MutS Homologue 2 and the Long-term Benefit of Adjuvant Chemotherapy in Lung Cancer
Authors:
- for the International Adjuvant Lung Trial-Bio investigatorsFIfor the International Adjuvant Lung Trial-Bio investigators
- Jean-Charles SoriaJSJean-Charles Soria
- Jean MendiboureJMJean Mendiboure
- David PlanchardDPDavid Planchard
- Ken A. OlaussenKOKen A. Olaussen
- Vanessa RousseauVRVanessa Rousseau
- Helmut PopperHPHelmut Popper
- Robert PirkerRPRobert Pirker
- Pascale BertrandPBPascale Bertrand
- Ariane DunantADAriane Dunant
- Thierry Le ChevalierTCThierry Le Chevalier
- 15 February 2010
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 16 (4) , 1206-1215
Abstract
Purpose: We sought to determine the long-term (median follow-up, 7.5 years) predictive power of human MutS homologue 2 (MSH2) immunohistochemical expression in patients who enrolled in the International Adjuvant Lung Trial. Experimental design: We tested the interaction between MSH2 and the allocated treatment (chemotherapy versus observation) in a Cox model adjusted on clinicopathologic variables. The significance level was set at 0.01. Results: MSH2 levels were low in 257 (38%) and high in 416 (62%) tumors. The benefit from chemotherapy was likely different according to MSH2 (interaction test, P = 0.06): there was a trend for chemotherapy to prolong overall survival when MSH2 was low [hazard ratio (HR), 0.76; 95% confidence interval (95% CI), 0.59-0.97; P = 0.03], but not when MSH2 was high (HR, 1.12; 95% CI, 0.81-1.55; P = 0.48). In the control arm, the HR was 0.66 (95% CI, 0.49-0.90; P = 0.01) when MSH2 was high. When combining MSH2 with excision repair cross-complementing group 1 (ERCC1) into four subgroups, the benefit of chemotherapy decreased with the number of markers expressed at high levels (P = 0.01). A similar decrease was noted when combining MSH2 and P27 (P = 0.01). Chemotherapy prolonged overall survival in the combined low MSH2/low ERCC1 subgroup (HR, 0.65; 95% CI, 0.47-0.91; P = 0.01) and in the combined low MSH2/low P27 subgroup (HR, 0.65; 95% CI, 0.46-0.93; P = 0.01). Conclusions: MSH2 expression is a borderline significant predictor of a long-term benefit from adjuvant cisplatin-based chemotherapy in patients with completely resected lung cancer. MSH2 combined with ERCC1 or P27 may identify patients most likely to benefit durably from chemotherapy. Clin Cancer Res; 16(4); 1206–15Keywords
This publication has 41 references indexed in Scilit:
- Immunodetection of DNA Repair Endonuclease ERCC1-XPF in Human TissueCancer Research, 2009
- Adjuvant Paclitaxel Plus Carboplatin Compared With Observation in Stage IB Non–Small-Cell Lung Cancer: CALGB 9633 With the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study GroupsJournal of Clinical Oncology, 2008
- Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative GroupJournal of Clinical Oncology, 2008
- Prognostic significance of DNA repair proteins MLH1, MSH2 and MGMT expression in non‐small‐cell lung cancer and precursor lesionsHistopathology, 2008
- Platinum Resistance: The Role of DNA Repair PathwaysClinical Cancer Research, 2008
- Interstrand crosslink repair: can XPF-ERCC1 be let off the hook?Trends in Genetics, 2008
- Double-strand breaks induce homologous recombinational repair of interstrand cross-links via cooperation of MSH2, ERCC1-XPF, REV3, and the Fanconi anemia pathwayDNA Repair, 2007
- Cell Cycle Regulators and Outcome of Adjuvant Cisplatin-Based Chemotherapy in Completely Resected Non–Small-Cell Lung Cancer: The International Adjuvant Lung Cancer Trial Biologic ProgramJournal of Clinical Oncology, 2007
- ERCC1 and Non–Small-Cell Lung CancerNew England Journal of Medicine, 2007
- Searching for microsatellite mutations in coding regions in lung, breast, ovarian and colorectal cancersOncogene, 2001